| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Di | C4 Therapeutics auf der Jefferies Healthcare Conference: Cemsidomide soll Basistherapie bei Multiplem Myelom werden | 2 | Investing.com Deutsch | ||
| C4 THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 09.11. | C4 Therapeutics forciert Cemsidomid: Vielversprechende Daten und klare Kombinationsstrategie beim multiplen Myelom | 2 | Investing.com Deutsch | ||
| 05.11. | C4 Therapeutics, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 05.11. | C4 Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 02.11. | C4 Therapeutics, Inc.: C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | 2 | GlobeNewswire (USA) | ||
| 29.10. | C4 Therapeutics unveils DEL technology for drug discovery | 3 | Investing.com | ||
| 09.10. | JPMorgan startet Coverage für C4 Therapeutics mit "Overweight" | 2 | Investing.com Deutsch | ||
| 09.10. | JPMorgan initiates C4 Therapeutics stock coverage at Overweight | 1 | Investing.com | ||
| 25.09. | C4 Therapeutics präsentiert Biomarker-Daten aus Studie zu Cemsidomid | 2 | Investing.com Deutsch | ||
| 25.09. | C4 Therapeutics presents cemsidomide trial biomarker data | 2 | Investing.com | ||
| 25.09. | C4 Therapeutics, Inc.: C4 Therapeutics Presents New Biomarker Data from the Cemsidomide Phase 1 Trial with Dexamethasone and Phase 1b Trial with Elranatamab (ELREXFIO) in Relapsed/Refractory Multiple Myeloma at the 23rd International Myeloma ... | 1 | GlobeNewswire (USA) | ||
| 25.09. | C4 Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 10.09. | C4 Therapeutics auf der Wells Fargo Konferenz: Cemsidomide im Mittelpunkt der Strategie | 3 | Investing.com Deutsch | ||
| 11.08. | C4 Therapeutics, Inc. - 10-Q, Quarterly Report | 2 | SEC Filings | ||
| 11.08. | C4 Therapeutics GAAP EPS of -$0.18 beats by $0.05, revenue of $6.64M beats by $2.64M | 1 | Seeking Alpha | ||
| 11.08. | C4 Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 10.08. | C4 Therapeutics, Inc.: C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | 1 | GlobeNewswire (USA) | ||
| 24.06. | C4 Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 11.06. | C4 Therapeutics presents cemsidomide data at EHA congress | 2 | Investing.com | ||
| 11.06. | C4 Therapeutics, Inc.: C4 Therapeutics Presents Phase 1 Data at European Hematology Association (EHA) 2026 Congress Highlighting Cemsidomide as a Potential Best-in-Class IKZF1/3 Degrader for Multiple Myeloma in Heavily Pretreated Relapsed/Refractory ... | 2 | GlobeNewswire (USA) |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIOFRONTERA | 2,680 | -4,63 % | Biofrontera AG: Was hinter der Nasdaq-Mitteilung steckt | ||
| OCUGEN | 0,709 | +1,29 % | Ocugen: Lizenzdeal mit Celairis - die Aktie sucht Halt | ||
| INOVIO PHARMACEUTICALS | 1,573 | -1,75 % | INOVIO PHARMACEUTICALS, INC. - 8-K, Current Report | ||
| CLINUVEL | 4,272 | -0,90 % | CLINUVEL PHARMACEUTICALS LIMITED: Change in substantial holding - Updated | ||
| INFLARX | 0,951 | -0,26 % | InflaRx im Check: Izicopan rückt vor, der Chart bleibt unter Druck | ||
| INTELLIA THERAPEUTICS | 9,070 | -0,98 % | Intellia Therapeutics (NTLA) Emerges as a Bright Spot Amid Tech Selloff | ||
| DEFENCE THERAPEUTICS | 0,135 | -11,51 % | Defence Therapeutics Inc.: Defence Therapeutics Invites Shareholders to Its December 10, 2026, Annual General Meeting and 2027 Strategic Update | Montreal, Quebec--(Newsfile Corp. - November 16, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a publicly traded biotechnology and precision intracellular... ► Artikel lesen | |
| EDITAS MEDICINE | 1,510 | +1,00 % | Editas Medicine, Inc.: Editas Medicine Receives Approval to Initiate First-In-Human Clinical Trial of EDIT-401 in Patients with Hyperlipidemia | Phase 1/2 clinical trial of EDIT-401 cleared to initiate dosing in patients who require additional LDL-C lowering Company remains on track to begin patient dosing this year and report initial safety... ► Artikel lesen | |
| BIOCRYST PHARMACEUTICALS | 6,580 | -0,27 % | BioCryst Pharmaceuticals, Inc.: BioCryst Announces Formation of Scientific Advisory Board to Drive Rare Disease Pipeline Innovation and Growth | -Supports BioCryst's evolution toward a more disciplined R&D model centered on external innovation- RESEARCH TRIANGLE PARK, N.C., Oct. 05, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:... ► Artikel lesen | |
| CARDIOL THERAPEUTICS | 0,800 | +1,78 % | Bayer, Cardiol Therapeutics, Novartis - Biotech-Aktien und Pharmariesen im Wettlauf ums Herz | Erstellt und veröffentlicht im Auftrag von Cardiol Therapeutics Die Kardiologie gehört zu den spannendsten Feldern der Pharmabranche. Vier Tage in Chicago haben gezeigt, wie viel Bewegung in der Herzmedizin... ► Artikel lesen | |
| GERON | 0,800 | +0,98 % | Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
| IBIO | 0,700 | -2,85 % | iBio, Inc. - 8-K, Current Report | ||
| IMMUNITYBIO | 5,550 | +0,91 % | ImmunityBio, Inc.: ImmunityBio to Participate in UK Investor Conferences During London Life Sciences Week 2026 | Senior leadership will discuss ImmunityBio's clinical and commercial priorities at Jefferies Global Healthcare Conference and UBS Global Biopharma Conference in London
ImmunityBio, Inc. (NASDAQ:... ► Artikel lesen | |
| ARBUTUS BIOPHARMA | 3,660 | 0,00 % | Arbutus Biopharma Corporation: Arbutus Announces Final Results of Its US$230 Million Modified "Dutch Auction" Tender Offer | WARMINSTER, Pa., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) ("Arbutus" or the "Company"), a clinical-stage biopharmaceutical company focused on infectious disease... ► Artikel lesen | |
| IMMATICS | 5,275 | +0,29 % | Jefferies reiterates Immatics stock Buy rating after conference |